PRN: Research and Markets - Biopharmaceutical Contract Manufacturing Market (2017-2027) - Characterized By a Number of Blockbuster Therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®

23/giu/2017 14:00:21 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Biopharmaceutical Contract Manufacturing Market (2017-2027) - Characterized By a Number of Blockbuster Therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®

 
[23-June-2017]
 

DUBLIN, June 23, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027" report to their offering.

Research and Markets Logo

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of producttherapy candidates, the market is poised for significant growth in the coming years.

It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics, which are currently under development, and biosimilars, which are generic versions of these biologics. The field continues to witness significant growth in terms of innovation; this activity is clearly indicative of the growing demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These complications have led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers.

As a result of the above mentioned industry dynamics, the contract manufacturing industry landscape is steadily evolving. CMOs aiming to consolidate their presence in the market are rapidly expanding their service portfolios to provide end-to-end services to their clients and sponsors.

Companies Mentioned

  • 3P Biopharmaceuticals
  • Aalto Scientific
  • AbbVie Contract Manufacturing
  • AbGenomics
  • Ablynx
  • Abzena
  • ACES Pharma
  • Acticor Biotech
  • Active Biotech
  • Adar Biotech
  • ADC Therapeutics
  • Adimab
  • Advanced BioScience Laboratories (ABL)
  • Advanced Biotherapeutics Consulting (ABC)
  • Affimed
  • Affinity Life Sciences
  • Agensys
  • Ajinomoto Althea
  • Albany Molecular Research (AMRI)
  • Alberta Cell Therapy Manufacturing
  • (400+ Others)

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. COMPETITIVE LANDSCAPE

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA AND THE REST OF THE WORLD

8. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING

9. CASE STUDY: OUTSOURCING OF BIOSIMILARS

10. RECENT DEVELOPMENTS

11. CAPACITY ANALYSIS

12. SURVEY ANALYSIS

13. OPPORTUNITY ANALYSIS

14. SWOT ANALYSIS

15. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

For more information about this report visit https://www.researchandmarkets.com/research/whhvnh/biopharmaceutical

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl